Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients

Condition:   Asthma Interventions:   Drug: Budesonide 200 microgram/Puff, HFA MDI;   Drug: Budesonide 100 microgram/Actuation Powder for Inhalation Sponsors:   Intech Biopharm Ltd.;   GCP ClinPlus Co., Ltd.;   Beijing Aicomer Pharmaceutical Technology Co., Ltd.;   Key Tech;   Healthcare Inc;   Peking University People's Hospital;   Beijing Friendship Hospital;   Tianjin First Central Hospital;   Bao Gang Hospital;   The Affili ated Hospital of Inner Mongolia Medical University;   Beijing Yi Hua Hospital Management Co., Ltd;   The Second Hospital of Hebei Medical University;   The First Affiliated Hospital of Shanxi Medical University;   Shaanxi Provincial People's Hospital;   Jining Medical Universit y;   Qingdao Municipal Hospital;   Daqing Oil Field Hospital;   First Affiliated Hospital of Jinan University;   Meizhou People's Hospital;   Meiheko Central Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials